. home.aspx



CVS launches precision medicine program for oncology

December 12, 2019 / Rebecca Pifer

CVS Health unveiled a precision medicine program for oncology patients Thursday designed to increase access to broad-panel gene sequencing tests for patients with specific advanced stage cancers. The Woonsocket, Rhode Island-based healthcare behemoth is partnering with Tempus, a precision medicine company, to help clinicians develop a personalized regimen for cancer patients to limit disease progression and reduce unnecessary costs. Results from the genetic tests will also be used to match eligible patients to clinical trials in their area. CVS-owned payer Aetna has already adopted the program for its fully insured commercial beneficiaries and is rolling it out with participating Aetna provider networks in 12 states.